Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Thoracic 3Other hematologic neoplasm 3

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × obatoclax × Thoracic × Clear all
NCT00405951 2016-07-21

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
47 enrolled
Thoracic

Lung Neoplasms

NCT00682981 2016-07-21

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
218 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00521144 2015-05-05

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
22 enrolled 9 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡